Point of Care Diagnostics:
A Clinician's View 2021

An annual review of U.S. clinicians’
expectations and experiences
with diagnostics

Survey of clinicians highlights critical need to address gaps in speed, accuracy and costs of Point of Care diagnostics

LumiraDx first Annual survey of US physicians reveals attitudes and perceptions of laboratory and point of care diagnostic tests.

December 07, 2021 (London, UK): Today, LumiraDx, a next-generation point of care diagnostics company shared the findings from its first annual survey “Point of Care Diagnostics: A Clinician’s View.”

The blinded survey conducted in September of 2021 was commissioned to obtain an in-depth understanding of clinicians’ pain points and perceptions surrounding point of care (POC) and laboratory diagnostics today.

Key findings include:


Pooja Pathak, LumiraDx’s Chief Product Officer explained, “While the last 18 months have shown the impact of point of care testing in fighting the pandemic, the question now is what technologies and products will drive transformation of the diagnostic industry as a whole and enable diagnostic decisions to made closer to patients?”

She continued, “The survey results reiterate clinicians’ desire to get fast and accurate diagnostic results in community care settings. They also highlight the need for innovative solutions that can deliver this speed and performance for a broad menu of tests cost effectively in a single platform.”

The third-party online poll, conducted anonymously, surveyed 300 U.S. physicians made up of 150 primary care clinicians and 150 urgent care clinicians. More details on this survey and other findings may be found here.

About LumiraDx

LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. The company has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, the company has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

LumiraDx is based in the UK with more than 1500 employees worldwide

Further information on LumiraDx and the LumiraDx Platform is available at lumiradx.com